MATHIAS

New Molecular-Functional Imaging Technologies and Therapeutic Strategies for Theranostic of Invasive Aspergillosis

 Coordinatore EBERHARD KARLS UNIVERSITAET TUEBINGEN 

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Bernd
Cognome: Pichler
Email: send email
Telefono: +49 7071 29 83427
Fax: +49 7071 20 4451

 Nazionalità Coordinatore Germany [DE]
 Totale costo 7˙932˙568 €
 EC contributo 5˙987˙541 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2018-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Bernd
Cognome: Pichler
Email: send email
Telefono: +49 7071 29 83427
Fax: +49 7071 20 4451

DE (TUEBINGEN) coordinator 1˙539˙364.00
2    ISCA DIAGNOSTICS LIMITED

 Organization address address: TREGOLIS ROAD LOWIN HOUSE
city: TRURO
postcode: TR1 2NA

contact info
Titolo: Mr.
Nome: Robert
Cognome: Misselbrook
Email: send email
Telefono: +44 01326 255695

UK (TRURO) participant 1˙397˙799.60
3    UNIVERSITAETSKLINIKUM ESSEN

 Organization address address: HUFELANDSTRASSE 55
city: ESSEN
postcode: 45147

contact info
Titolo: Prof.
Nome: Matthias
Cognome: Gunzer
Email: send email
Telefono: +49 201 183 6640

DE (ESSEN) participant 1˙110˙540.40
4    CHEMATECH SAS

 Organization address address: RUE DU BAS DE CHANOT 7
city: CHEVIGNY SAINT SAUVEUR
postcode: 21800

contact info
Titolo: Dr.
Nome: Frédéric
Cognome: Boschetti
Email: send email
Telefono: +33 642427123
Fax: +33 380396117

FR (CHEVIGNY SAINT SAUVEUR) participant 1˙006˙110.00
5    PAUL SCHERRER INSTITUT

 Organization address address: Villigen
city: VILLIGEN PSI
postcode: 5232

contact info
Titolo: Mrs.
Nome: Irene
Cognome: Walthert
Email: send email
Telefono: +41 56 3102664

CH (VILLIGEN PSI) participant 531˙350.00
6    DANMARKS TEKNISKE UNIVERSITET

 Organization address address: Anker Engelundsvej 1, Building 101A
city: KONGENS LYNGBY
postcode: 2800

contact info
Titolo: Prof.
Nome: Mikael
Cognome: Jensen
Email: send email
Telefono: +45 26255890
Fax: +45 46775347

DK (KONGENS LYNGBY) participant 402˙377.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

diagnosis    infectious    risk    patients    antifungal    tracers    immuno    treatment    fumigatus    pet    imaging    severe    invasive    drugs    technologies    combined    rare    ia    disease    definitive   

 Obiettivo del progetto (Objective)

'The development of novel technologies to diagnose and clinically treat invasive Aspergillus fumigatus infections is the scope of this research consortium. A. fumigatus is a ubiquitous mould whose spores are airborne and thus frequently inhaled. Humans with impaired immunity, e.g. those with haematological malignancies or bone marrow transplant recipients, are at a dramatically increased risk of severe, invasive A. fumigatus infection known as invasive aspergillosis (IA). IA is a rare disease in Europe but causes tremendous costs to the public health sector. Currently definitive diagnosis of IA is only obtained at autopsy or relies on invasive biopsy, an extremely unpleasant procedure which is not always applicable in suffering patients. Thus, a convenient, fast and specific diagnosis of IA is not available forcing clinicians to administer antifungal drugs on spec if a standard antibiotic treatment failed to reduce fever in risk patients. It would be of high financial benefit for clinics and has the potential to increase the survival rates of immuno-compromised patients, if a definitive diagnosis of IA could be obtained early and its response to treatment be monitored. This would allow applying the correct therapy at a dose and duration exactly tailored to patient needs. Equally important is the development of new treatment options which can replace existing systemic antifungal drugs with their known severe side effects. The approach of the consortium is to develop new disease specific tracers based on monoclonal antibodies along with the combined molecular imaging technologies PET/MR and PET/CT. Newly developed tracers shall then be functionalised by a combined labelling with radio-isotopes allowing diagnostic PET imaging but also immuno-radiotherapy, thus representing truly anti-infectious theranostics. This would provide a framework for new tools in the management not only of this rare but life-threatening mycosis but principally also for other infectious hazards.'

Altri progetti dello stesso programma (FP7-HEALTH)

CANCERPATHWAYS (2008)

Developmental Molecular Pathways in Drosophila as a Model for Human Cancer

Read More  

RAPTADIAG (2012)

Rapid Aptamer based diagnostics for bacterial meningitis

Read More  

CAREPNEUMO (2009)

Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on in vivo and in vitro Host – Pathogen Interactions

Read More